Patient Selection: With most cardiovascular patients having BMI 27 kg/m, this represents a large eligible population who may derive cardiovascular benefit from semaglutide, independent of achieving substantial weight reduction
Because the shakes are shelf stable, they are also well suited for different dayparts such as after a workout at the gym or on the go when a refrigerated product like Oikos Fusion may not be appropriate
Based on the available data, tirzepatide has the lowest discontinuation rates and similar or slightly lower GI side effect rates compared to semaglutide
B., Appa, Y., Bhandarkar, S
The Gala GLP-1 health assessment requests disclosure of all current medications including but not limited to insulin, sulfonylureas, oral contraceptives, and certain anticoagulants for provider review
Who is at Risk for Ozempic Teeth? Its important to note that not everyone on GLP-1 agonists will experience Ozempic teeth. Several factors can influence an individuals susceptibility